Biotechnology
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

$143.9M

Market Cap • 4/3/2025

1995

(30 years)

Founded

2024

(1 year ago)

IPO

NASDAQ

Listing Exchange

Flag of US

Tampa

Headquarters • Florida